The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients may predict therapeutic outcome.
 
Gehan Botrus
No Relationships to Disclose
 
Yu Fu
Employment - Guardant Health; Takeda
Stock and Other Ownership Interests - Gilead Sciences; Moderna Therapeutics; Pfizer; Takeda
Research Funding - Guardant Health; Takeda
Travel, Accommodations, Expenses - Takeda
 
Mohamad Bassam Sonbol
No Relationships to Disclose
 
Leylah Drusbosky
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Daniel H. Ahn
Consulting or Advisory Role - Celltrion (I); Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Jason S. Starr
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Ipsen; Natera; Pfizer
Research Funding - Incyte (Inst); Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Natera; Rafael Pharmaceuticals (Inst); Vedanta Biosciences (Inst)
 
Jeremy Clifton Jones
No Relationships to Disclose
 
Puneet Raman
No Relationships to Disclose
 
Kabir Mody
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Ipsen; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; AstraZeneca (Inst); Basilea (Inst); FibroGen; Gritstone Bio (Inst); Incyte (Inst); MedImmune; Merck (Inst); Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma; Turnstone Bio (Inst); Vyriad (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Bayer (Inst); Celgene (Inst); Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - ARMO BioSciences; AstraZeneca; Exelixis; Lilly; Merck (Inst); Sillajen